Home » Stocks » ZGNX

Zogenix, Inc. (ZGNX)

Stock Price: $16.21 USD -0.09 (-0.55%)
Updated Jul 30, 2021 4:00 PM EDT - Market closed
After-hours: $16.10 -0.11 (-0.68%) Jul 30, 7:09 PM
Market Cap 904.72M
Revenue (ttm) 26.08M
Net Income (ttm) -239.21M
Shares Out 55.75M
EPS (ttm) -4.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 30
Last Price $16.21
Previous Close $16.30
Change ($) -0.09
Change (%) -0.55%
Day's Open 16.14
Day's Range 15.90 - 16.44
Day's Volume 407,656
52-Week Range 15.72 - 25.88

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

EMERYVILLE, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Zogenix, a global biopharmaceutical company developing rare disease therapies, and ten U.S. advocacy groups today announced the launch of  VIP Sibli...

2 weeks ago - GlobeNewsWire

EMERYVILLE, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that members of it...

1 month ago - GlobeNewsWire

EMERYVILLE, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen J. Far...

2 months ago - GlobeNewsWire

Zogenix (ZGNX) delivered earnings and revenue surprises of -2.04% and 9.65%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Zogenix (NASDAQ:ZGNX) moved higher in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 85.19% year over year to ($1.00), which beat the est...

2 months ago - Benzinga

EMERYVILLE, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced financial results f...

2 months ago - GlobeNewsWire

Zogenix (ZGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Zogenix Inc (NASDAQ: ZGNX) has announced new data showing the positive impact of treatment with Fintepla (fenfluramine) on everyday executive function for children and young adults with Lennox-Gastaut s...

3 months ago - Benzinga

EMERYVILLE, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced new data showing the positive impact ...

3 months ago - GlobeNewsWire

EMERYVILLE, Calif., April 16, 2021 (GLOBE NEWSWIRE) --  Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced new findings from an investigator-in...

3 months ago - GlobeNewsWire

EMERYVILLE, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen J. F...

3 months ago - GlobeNewsWire

EMERYVILLE, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today provided a corporate update ...

5 months ago - GlobeNewsWire

Zogenix (ZGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

EMERYVILLE, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will report its financial resu...

5 months ago - GlobeNewsWire

EMERYVILLE, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, announced today that FINTEPLA® (fenfluramine) oral sol...

6 months ago - GlobeNewsWire

EMERYVILLE, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today reported select preliminary,...

6 months ago - GlobeNewsWire

After an incredibly wild and wooly year for investors, many across Wall Street are cautiously optimistic for 2021.

Other stocks mentioned: ACAD, NBIX, QURE, VRTX
7 months ago - 24/7 Wall Street

EMERYVILLE, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, announced today that the European Commission (EC) has ...

7 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and EMERYVILLE, Calif., Dec. 3, 2020 /PRNewswire/ -- Tevard Biosciences, a privately-held biotechnology company pioneering tRNA-based gene therapies, and Zogenix (Nasdaq: ZGNX), a globa...

7 months ago - PRNewsWire

As COVID surges to unprecedented levels with additional shutdown measures taking place, markets declined to close what has been a largely strong November. Using our deep learning algorithms, our AI has ...

Other stocks mentioned: CALM, CRNC, TPIC, TRUP
8 months ago - Forbes

Zogenix just launched Fintepla, a product to treat Dravet syndrome. GW Pharma already has a Fintepla competitor Epidiolex approved and growing big sales in Dravet syndrome and other indications that Fin...

8 months ago - Seeking Alpha

Zogenix's (ZGNX) CEO Stephen Farr on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Zogenix (ZGNX) delivered earnings and revenue surprises of -0.99% and 50.05%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

EMERYVILLE, Calif. , Nov. 09, 2020 (GLOBE NEWSWIRE) --  Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced financial result...

8 months ago - GlobeNewsWire

Zogenix (ZGNX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

8 months ago - Zacks Investment Research

In this article we will take a look at whether hedge funds think Zogenix, Inc. (NASDAQ:ZGNX) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into ho...

8 months ago - Insider Monkey

Zogenix (ZGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research

EMERYVILLE, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it has changed the date of ...

9 months ago - GlobeNewsWire

Shares of Zogenix have been under pressure lately due to safety concerns surrounding its unique anti-epileptic drug, Fintepla. Despite receiving FDA approval for a rare and serious epileptic condition, ...

9 months ago - Seeking Alpha

EMERYVILLE, Calif., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that the Committee for Medicinal Produ...

9 months ago - GlobeNewsWire

EMERYVILLE, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a global biopharmaceutical company developing rare disease therapies, shared new data analyses for FINTEPLA® (fenflura...

9 months ago - GlobeNewsWire

EMERYVILLE, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that the initial purchasers of t...

9 months ago - GlobeNewsWire

EMERYVILLE, Calif., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, and its subsidiary Modis The...

9 months ago - GlobeNewsWire

Thesis that FDA approval of Fintepla would immediately unlock value was wrong. With ZGNX down nearly 40% since, and the story still fully intact, the stock is now highly attractive.

10 months ago - Seeking Alpha

EMERYVILLE, Calif., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX) today announced the pricing of its offering of $200,000,000 aggregate principal amount of 2.75% convertible senior n...

10 months ago - GlobeNewsWire

EMERYVILLE, Calif., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX) today announced its intention to offer, subject to market and other conditions, $200,000,000 aggregate principal amo...

10 months ago - GlobeNewsWire

Correction: In this updated news release issued September 21, 2020 by Zogenix, Inc, the name of the organization, WorldWideWomen, has been corrected. The full corrected press release follows.

10 months ago - GlobeNewsWire

EMERYVILLE, Calif., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced the appointment...

10 months ago - GlobeNewsWire

EMERYVILLE, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today reported positive top-lin...

10 months ago - GlobeNewsWire

Zogenix's (ZGNX) CEO Stephen Farr on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Zogenix (ZGNX) delivered earnings and revenue surprises of 5.88% and -6.18%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

EMERYVILLE, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced financial...

11 months ago - GlobeNewsWire

EMERYVILLE, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial...

1 year ago - GlobeNewsWire

Zogenix (ZGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

It’s been a bumpy ride for Zogenix Inc. (NASDAQ:ZGNX) shareholders over the past three years, but at just more than $29, the stock is well below its average 12-month price target of $44.60.

1 year ago - GuruFocus

Zogenix (ZGNX) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

Zogenix: Market Reaction To Fintepla's Approval Offers A Gift To Investors

1 year ago - Seeking Alpha

Shares of Zogenix Inc. ZGNX, -9.42% gained 2.9% in premarket trading on Monday, following the news on Friday that the Food and Drug Administration had approved Fintepla, its treatment for seizures assoc...

1 year ago - Market Watch

Zogenix (ZGNX) gets FDA nod for Fintepla oral solution, CIV for the treatment of seizures associated with Dravet Syndrome in patients 2 years of age or older.

1 year ago - Zacks Investment Research

EMERYVILLE, Calif., June 25, 2020 /PRNewswire/ -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that the U.S. Food and Drug Administrat...

1 year ago - PRNewsWire

About ZGNX

Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also... [Read more...]

Industry
Biotechnology
IPO Date
Nov 23, 2010
CEO
Stephen Farr
Employees
218
Stock Exchange
NASDAQ
Ticker Symbol
ZGNX
Full Company Profile

Financial Performance

In 2020, Zogenix's revenue was $13.64 million, an increase of 273.99% compared to the previous year's $3.65 million. Losses were -$209.38 million, -50.09% less than in 2019.

Financial Statements

Analyst Forecasts

According to 13 analysts, the average rating for Zogenix stock is "Buy." The 12-month stock price forecast is 48.22, which is an increase of 197.47% from the latest price.

Price Target
$48.22
(197.47% upside)
Analyst Consensus: Buy